EU vs US: the legal picture

Why can a compound be lawfully prepared by a pharmacy in the United States yet be unlawful to sell as a medicine in the European Union? Because the two systems ask different questions. This note sketches the picture at a high level — it is context, not legal advice.

Two different questions

• The EU asks, in effect: does this product have a marketing authorisation, or is it an ordinary cosmetic? An unapproved injectable peptide has neither footing, so it is neither sold nor advertised as a medicine.
• The US has an additional lane: compounding. Under §503A, a licensed pharmacy may prepare certain preparations for an individual patient — a clinician's decision, routed through a pharmacy, never an e-commerce checkout.

Where cosmetics sit

Topical cosmetic peptides are governed as cosmetics — in the EU under Regulation (EC) 1223/2009. That is the one lawful lane this shop uses. A cosmetic makes appearance-and-feel claims; it does not make medical claims.

What this means on Vallydia

• Cosmetic peptides: sold openly where lawful.
• Research compounds: documented as neutral reference entries, never sold here.
• Compoundable compounds (US): we point to the lawful pharmacy channel as information — status only, never a cart.

The difference is encoded in each entry's lane and status, so what you can do on a page always matches what is lawful where you are.